{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:55Z","timestamp":1791568855712,"version":"4.3.4"},"reference-count":25,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nuklearmedizin"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2002In somatostatin receptor (SSTR) expressing progressive meningioma, peptide receptor radionuclide therapy (PRRT) has shown effect in small clinical series. However, standardized treatment and response assessment protocols are lacking. We present our experience on PPRT with 177Lu-DOTATATE in progressive meningioma with a special emphasis on state-of-the-art response assessment.<\/jats:p><jats:p>\n          Methods\u2002Retrospective analysis on PRRT with 177Lu-DOTATATE from 2015 to 2019. Pre- and post-therapy imaging was performed using MRI and 68Ga-DOTATATE-PET for standard bidimensional and volumetric analyses, respectively, following novel RANO guidelines.<\/jats:p><jats:p>\n          Results\u2002Seven patients with progressive intracranial meningioma (median age 73 years, interquartile range 60\u201376; 5\u00a0WHO II, 2 WHO I; 5 multifocal) received a median of 4 cycles 2\n          3\n          4 of PRRT with 177Lu-DOTATATE in eight-week intervals. Three patients did not undergo post-therapy 68Ga-DOTATATE-PET due to early symptomatic progression and subsequent cessation of PRRT. After completion of 4 PRRT cycles volumetric PET imaging showed stable disease in two of four patients. According to bidimensional MRI response assessment, only one patient was stable. Progression free survival at six months was 42.9\u200a%.<\/jats:p><jats:p>\n          Conclusion\u2002In this heterogeneous collective of seven patients with progressive meningioma, 177Lu-DOTATATE therapies showed heterogeneous effectiveness. PET-based volumetric assessment should be used for response assessment in PRRT additionally to bidimensional imaging.<\/jats:p>","DOI":"10.1055\/a-1200-0989","type":"journal-article","created":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T23:23:46Z","timestamp":1595287426000},"page":"348-355","source":"Crossref","is-referenced-by-count":19,"title":["Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma"],"prefix":"10.1055","volume":"59","author":[{"given":"Michael","family":"M\u00fcther","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Roll","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Brokinkel","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Zinnhardt","sequence":"additional","affiliation":[{"name":"European Institute of Molecular Imaging, WWU, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Sporns","sequence":"additional","affiliation":[{"name":"Institute of Clinical Radiology, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Seifert","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[{"name":"European Institute of Molecular Imaging, WWU, M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Weckesser","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Stegger","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Stummer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kambiz","family":"Rahbar","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, University Hospital M\u00fcnster, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-009-1115-z","article-title":"Peptide receptor radionuclide therapy with 90Y-DOTATOC in recurrent meningioma","volume":"36","author":"M Bartolomei","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"R Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1093\/neuonc\/nox112","article-title":"PET imaging in patients with meningioma-report of the RANO\/PET Group","volume":"19","author":"N Galldiks","year":"2017","journal-title":"Neuro Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.2967\/jnumed.115.155853","article-title":"90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas","volume":"56","author":"K Gerster-Gillieron","year":"2015","journal-title":"J Nucl Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1470-2045(16)30321-7","article-title":"EANO guidelines for the diagnosis and treatment of meningiomas","volume":"17","author":"R Goldbrunner","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00259-018-4221-y","article-title":"Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy","volume":"46","author":"E Guedj","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/neuonc\/noy137","article-title":"Proposed response assessment and endpoints for meningioma clinical trials: Report from the Response Assessment in Neuro-Oncology Working Group","volume":"21","author":"R Y Huang","year":"2019","journal-title":"Neuro Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.114.148437","article-title":"Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE","volume":"56","author":"E Ilan","year":"2015","journal-title":"J Nucl Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1748-717X-7-99","article-title":"Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"7","author":"M C Kreissl","year":"2012","journal-title":"Radiat Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy","volume":"10","author":"E P Krenning","year":"1999","journal-title":"Ann Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/a-0987-9689","article-title":"[Evaluation of intratherapeutic 177Lu-HA-DOTATATE treatment in neuroendocrine tumors: dosimetry with SPECT, whole-body imaging and gamma probe]","volume":"58","author":"B Leonh\u00e4user","year":"2019","journal-title":"Nuklearmedizin"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/RLU.0000000000000669","article-title":"Rhabdoid Papillary Meningioma Treated With 177Lu DOTATATE PRRT","volume":"40","author":"W Makis","year":"2015","journal-title":"Clin Nucl Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2967\/jnumed.114.147256","article-title":"Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in\u00a0progressive meningioma: long-term results of a phase II clinical trial","volume":"56","author":"N Marincek","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/cbr.2013.1599","article-title":"Peptide Receptor Radionuclide Therapy in Patients with Inoperable Meningiomas: Our Experience and Review of the Literature","volume":"29","author":"F Minutoli","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"issue":"S 01","key":"ref15","first-page":"92S","article-title":"Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs","volume":"46","author":"S Pauwels","year":"2005","journal-title":"J Nucl Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2967\/jnumed.114.149120","article-title":"Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue","volume":"56","author":"W Rachinger","year":"2015","journal-title":"J\u00a0Nucl Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"J C Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"ref18","first-page":"1","article-title":"177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer","author":"W Roll","year":"2018","journal-title":"Clin Nucl Med"},{"key":"ref19","first-page":"1538","article-title":"Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE\/-TOC uptake","volume":"18","author":"K Seystahl","year":"2016","journal-title":"Neuro Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/neuonc\/now001","article-title":"68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate?","volume":"18","author":"M Sommerauer","year":"2016","journal-title":"Neuro Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"J Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1055\/a-0802-5039","article-title":"Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET\/CT in patients with inoperable meningioma","volume":"58","author":"F A Verburg","year":"2019","journal-title":"Nuklearmedizin"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors","volume":"50","author":"R L Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","article-title":"The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours","volume":"40","author":"J J Zaknun","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref25","volume-title":"Long-term Nephrotoxicity After PRRT: Mythos or Reality?","author":"J Zhang","year":"2019","edition":"V47"}],"container-title":["Nuklearmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1200-0989.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T22:34:59Z","timestamp":1601332499000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1200-0989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":25,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2020,9,28]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1200-0989","relation":{},"ISSN":["0029-5566","2567-6407"],"issn-type":[{"value":"0029-5566","type":"print"},{"value":"2567-6407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]}}}